The R&D chal­lenge: 4 top drug hunters talk best prac­tices in build­ing a biotech to­day

Last week I in­vit­ed 4 deeply ex­pe­ri­enced bio­phar­ma ex­ecs to gath­er for an hour to dis­cuss what they’ve learned over the years about de­vel­op­ing drugs. What were the key lessons that they’ve tak­en in­to new en­deav­ors? And what did they shed along the way? Tec­ton­ic CEO Alise Re­icin, an ex­pe­ri­enced Mer­ck vet who had a se­nior role in de­vel­op­ing Keytru­da, joined GV ex­ec David Schenkein, who found­ed Agios, along with Kite founder and cur­rent Al­lo­gene chair Arie Bellde­grun and for­mer Gilead CSO, now Kro­nos founder, Nor­bert Bischof­berg­er. It was a great con­ver­sa­tion, which you can fol­low along here. The tran­script has been edit­ed for style and brevi­ty. — John Car­roll

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER